Abdominal Obesity, Metabolic Syndrome, Disability Physical, Sarcopenic Obesity, Hypertension, Overweight and Obesity, Cardiovascular Risk Factor
Conditions
Brief summary
Monocentric unblinded two parallel-group randomized controlled trial to evaluate the effect of diet with or without Nordic Walking on weight loss, physical performance and cardiovascular risk factors in overweight and obese population
Detailed description
To examine the impact of a 48-week of diet +/- Nordic Walking program on physical performance, muscle function, cardiovascular risk factors and arterial stiffness in community-dwelling overweight and obese elderly men and women.
Interventions
BEHAVIORALDiet
52 weeks of Diet supervised by a dietician
BEHAVIORALWalking
26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
BEHAVIORALNordic Walking
26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
Sponsors
Universita di Verona
Azienda Ospedaliera Universitaria Integrata Verona
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Monocentric unblinded two parallel-group randomized controlled trial
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* 60-90 years * Males and females . BMI \> 27 kg/m2 * living in Verona (Italy) * stable weight in the 3 months * not involved in physical exercise programs * informed consent sign
Exclusion criteria
* cardiovascular disease (unstable angina, recent myocardial infarction, cardiac arrhythmias, heart failure, valvular heart disease, aortic aneurysm, recent intracerebral or subdural hemorrhage, not controlled hypertension) * musculoskeletal disease (symptomatic discal hernia, symptomatic arthrosis, acute articular, tendon or ligament lesions, hip prothesis).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VO2 max | 12 months | maximal oxygen consumption |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PWV | 3, 6, 9 and 12 months | pulse wave velocity |
| muscle strength | 3, 6, 9 and 12 months | — |
| fat mass | 3, 6, 9 and 12 months | — |
| VO2 max changes | 3, 6, 9 and 12 months | maximal oxygen consumption |
| SF 36 | 6 and 12 months | quality of life |
| GDS | 6 and 12 months | geriatric depression scale |
| muscle mass | 3, 6, 9 and 12 months | — |
Countries
Italy
Contacts
Primary ContactAndrea P Rossi, Md PhD
Outcome results
None listed